Pharma recruiting is broken in a very specific way.
Most hiring teams still treat “best scientists” like a vibe: impressive titles, familiar institutions, a few buzzwords in a CV. But in a world where R&D is increasingly constrained by patents, lit…

Pharma has a new playbook—and it’s not always about new science.
In a world where patients are told to “wait for innovation,” drug companies are increasingly finding another lever: repurposed medicines. The same active ingredient. A new indication. A f…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in global pharma—an obscure regulatory tweak that only lawyers and patent nerds notice. But the real story is what happens when you zoom out.
In a recent DrugPatentWatch analysis, the focus shift…

Big Pharma doesn’t always “win” patent fights. Sometimes it just… delays them.
Europe’s divisional patent strategy—where companies split one patent application into multiple follow-on filings—has become a quiet but powerful tool to keep generics off th…

Pharma patent litigation used to be a “cost of doing business.”
Now it’s a board-level crisis.
Drug patent watch recently highlighted a shift that many in the industry have felt but few have quantified: litigation budgets that once hovered around $50…

PBMs don’t just “manage formularies.” They shape the economics of every drug launch, every contract renewal, and—quietly but decisively—every patient’s access point. If you’re a pharma executive still treating PBM rebates as a back-office line item, yo…

Mark Cuban’s “cost-plus” pricing isn’t just a new way to buy drugs—it’s a direct challenge to the business model that has quietly governed the pharmaceutical industry for decades.
For years, the patent playbook has been remarkably consistent: innovate,…

Most founders ask the wrong question about provisional patents.
They don’t ask: “Will this help me win?”
They ask: “Should I file?”
That’s understandable—provisionals are marketed as fast, flexible, and relatively low-cost. But in drug development, whe…

Don’t Wait for the Patent Cliff: Build Supply-Chain Resilience Years Before Drug Patent Expiration
The “patent cliff” is often discussed like a weather event—something you can only react to once it hits.
But in pharma, the cliff isn’t a surprise. It’s …